Oakwood Labs believes that engaging in strategic partnerships with other organizations is essential to bringing enhanced pharmaceutical products to more patients. Oakwood has worked with a number of companies on important projects and we proudly consider ourselves a strong collaborator.
Oakwood Labs and Zoetis, the largest global animal health company, are building on a multi-year history of productive collaborations with a three-year agreement to develop and test sustained-release formulations. In addition to collaborating on research programs and compound delivery technologies for Zoetis, our companies are working together, pooling resources and expertise to advance and expand the Oakwood platform for a broader set of innovative applications. Resulting products could offer the advantage of longer-lasting efficacy and need for fewer injections in both humans and their companions.
Oakwood Labs and Edge Therapeutics, a clinical-stage biotechnology company, are collaborating now on the development of a sustained-release formulation of nimodipine using Oakwood’s Chroniject™ technology. This product has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemmorage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm.
Connect with us to learn more about how we can work together.